Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Radium-223 in Combination With Enzalutamide in Progressive Metastatic Castrate-Resistant Prostate Cancer

NCT02225704 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT02225704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02225704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Radium-223 in Combination With Enzalutamide in Progressive Metastatic Castrate-Resistant Prostate Cancer
Lead sponsor
Cancer Trials Ireland
Phase
Phase 2
Overall status
Completed
Start date
June 3, 2015
Completion date
November 23, 2021
Enrollment
45 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer